Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease

Joan D Beckman, John D Belcher, Julie V. Vineyard, Chunsheng Chen, Julia Nguyen, M. Osita Nwaneri, Gerard O'Sullivan, Evin Gulbahce, Robert P Hebbel, Gregory M Vercellotti

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Carbon monoxide (CO) has anti-inflammatory properties. We previously reported that acute treatments with inhaled CO inhibit vascular inflammation and hypoxia-induced vasoocclusion in sickle cell disease mouse models. Therefore, we hypothesized that chronic CO inhalation would decrease vascular inflammation and organ pathology in a sickle cell disease mouse model. The treatment of sickle cell disease mice with 25 or 250 parts/million inhaled CO for 1 h/day, 3 days/wk for 8-10 wk significantly decreased the total mean white blood cell, neutrophil, and lymphocyte counts in peripheral blood. Eight weeks of 250 parts/million CO treatments reduced staining for myeloid and lymphoid markers in the bone marrow of sickle mice. Bone marrow from treated sickle mice exhibited a significant decrease in colony-forming unit granulocyte-macrophage during colony-forming cell assays. Anti-inflammatory signaling pathways phospho-Akt and phospho-p38 MAPK were markedly increased in CO-treated sickle livers. Importantly, CO-treated sickle mice had a significant reduction in liver parenchymal necrosis, reflecting the anti-inflammatory benefits of CO. We conclude that inhaled CO may be a beneficial anti-inflammatory therapy for sickle cell disease.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume297
Issue number4
DOIs
StatePublished - Oct 1 2009

Fingerprint

Leukocytosis
Sickle Cell Anemia
Carbon Monoxide
Anti-Inflammatory Agents
Blood Vessels
Bone Marrow
Inflammation
Granulocyte-Macrophage Progenitor Cells
Liver
Lymphocyte Count
p38 Mitogen-Activated Protein Kinases
Leukocyte Count
Inhalation
Neutrophils
Necrosis
Pathology
Staining and Labeling

Keywords

  • Heme oxygenase
  • Inflammation

Cite this

@article{02c7202096974e84a650e1542a5a560d,
title = "Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease",
abstract = "Carbon monoxide (CO) has anti-inflammatory properties. We previously reported that acute treatments with inhaled CO inhibit vascular inflammation and hypoxia-induced vasoocclusion in sickle cell disease mouse models. Therefore, we hypothesized that chronic CO inhalation would decrease vascular inflammation and organ pathology in a sickle cell disease mouse model. The treatment of sickle cell disease mice with 25 or 250 parts/million inhaled CO for 1 h/day, 3 days/wk for 8-10 wk significantly decreased the total mean white blood cell, neutrophil, and lymphocyte counts in peripheral blood. Eight weeks of 250 parts/million CO treatments reduced staining for myeloid and lymphoid markers in the bone marrow of sickle mice. Bone marrow from treated sickle mice exhibited a significant decrease in colony-forming unit granulocyte-macrophage during colony-forming cell assays. Anti-inflammatory signaling pathways phospho-Akt and phospho-p38 MAPK were markedly increased in CO-treated sickle livers. Importantly, CO-treated sickle mice had a significant reduction in liver parenchymal necrosis, reflecting the anti-inflammatory benefits of CO. We conclude that inhaled CO may be a beneficial anti-inflammatory therapy for sickle cell disease.",
keywords = "Heme oxygenase, Inflammation",
author = "Beckman, {Joan D} and Belcher, {John D} and Vineyard, {Julie V.} and Chunsheng Chen and Julia Nguyen and Nwaneri, {M. Osita} and Gerard O'Sullivan and Evin Gulbahce and Hebbel, {Robert P} and Vercellotti, {Gregory M}",
year = "2009",
month = "10",
day = "1",
doi = "10.1152/ajpheart.00327.2009",
language = "English (US)",
volume = "297",
journal = "American Journal of Physiology - Cell Physiology",
issn = "0363-6143",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease

AU - Beckman, Joan D

AU - Belcher, John D

AU - Vineyard, Julie V.

AU - Chen, Chunsheng

AU - Nguyen, Julia

AU - Nwaneri, M. Osita

AU - O'Sullivan, Gerard

AU - Gulbahce, Evin

AU - Hebbel, Robert P

AU - Vercellotti, Gregory M

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Carbon monoxide (CO) has anti-inflammatory properties. We previously reported that acute treatments with inhaled CO inhibit vascular inflammation and hypoxia-induced vasoocclusion in sickle cell disease mouse models. Therefore, we hypothesized that chronic CO inhalation would decrease vascular inflammation and organ pathology in a sickle cell disease mouse model. The treatment of sickle cell disease mice with 25 or 250 parts/million inhaled CO for 1 h/day, 3 days/wk for 8-10 wk significantly decreased the total mean white blood cell, neutrophil, and lymphocyte counts in peripheral blood. Eight weeks of 250 parts/million CO treatments reduced staining for myeloid and lymphoid markers in the bone marrow of sickle mice. Bone marrow from treated sickle mice exhibited a significant decrease in colony-forming unit granulocyte-macrophage during colony-forming cell assays. Anti-inflammatory signaling pathways phospho-Akt and phospho-p38 MAPK were markedly increased in CO-treated sickle livers. Importantly, CO-treated sickle mice had a significant reduction in liver parenchymal necrosis, reflecting the anti-inflammatory benefits of CO. We conclude that inhaled CO may be a beneficial anti-inflammatory therapy for sickle cell disease.

AB - Carbon monoxide (CO) has anti-inflammatory properties. We previously reported that acute treatments with inhaled CO inhibit vascular inflammation and hypoxia-induced vasoocclusion in sickle cell disease mouse models. Therefore, we hypothesized that chronic CO inhalation would decrease vascular inflammation and organ pathology in a sickle cell disease mouse model. The treatment of sickle cell disease mice with 25 or 250 parts/million inhaled CO for 1 h/day, 3 days/wk for 8-10 wk significantly decreased the total mean white blood cell, neutrophil, and lymphocyte counts in peripheral blood. Eight weeks of 250 parts/million CO treatments reduced staining for myeloid and lymphoid markers in the bone marrow of sickle mice. Bone marrow from treated sickle mice exhibited a significant decrease in colony-forming unit granulocyte-macrophage during colony-forming cell assays. Anti-inflammatory signaling pathways phospho-Akt and phospho-p38 MAPK were markedly increased in CO-treated sickle livers. Importantly, CO-treated sickle mice had a significant reduction in liver parenchymal necrosis, reflecting the anti-inflammatory benefits of CO. We conclude that inhaled CO may be a beneficial anti-inflammatory therapy for sickle cell disease.

KW - Heme oxygenase

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=70349630108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349630108&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00327.2009

DO - 10.1152/ajpheart.00327.2009

M3 - Article

C2 - 19617415

AN - SCOPUS:70349630108

VL - 297

JO - American Journal of Physiology - Cell Physiology

JF - American Journal of Physiology - Cell Physiology

SN - 0363-6143

IS - 4

ER -